KR20030078805A - 유방암 예후 포트폴리오 - Google Patents

유방암 예후 포트폴리오 Download PDF

Info

Publication number
KR20030078805A
KR20030078805A KR10-2003-0019842A KR20030019842A KR20030078805A KR 20030078805 A KR20030078805 A KR 20030078805A KR 20030019842 A KR20030019842 A KR 20030019842A KR 20030078805 A KR20030078805 A KR 20030078805A
Authority
KR
South Korea
Prior art keywords
seq
portfolio
gene
expression
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR10-2003-0019842A
Other languages
English (en)
Korean (ko)
Inventor
왕이신
Original Assignee
오르토-클리니칼 다이아그노스틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29215884&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20030078805(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 오르토-클리니칼 다이아그노스틱스, 인코포레이티드 filed Critical 오르토-클리니칼 다이아그노스틱스, 인코포레이티드
Publication of KR20030078805A publication Critical patent/KR20030078805A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
KR10-2003-0019842A 2002-03-29 2003-03-29 유방암 예후 포트폴리오 Withdrawn KR20030078805A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36878902P 2002-03-29 2002-03-29
US60/368,789 2002-03-29

Publications (1)

Publication Number Publication Date
KR20030078805A true KR20030078805A (ko) 2003-10-08

Family

ID=29215884

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2003-0019842A Withdrawn KR20030078805A (ko) 2002-03-29 2003-03-29 유방암 예후 포트폴리오

Country Status (11)

Country Link
US (1) US7473526B2 (https=)
EP (1) EP1367138B1 (https=)
JP (1) JP2003325192A (https=)
KR (1) KR20030078805A (https=)
CN (1) CN1495274A (https=)
AR (1) AR039213A1 (https=)
AU (1) AU2003203557B2 (https=)
BR (1) BR0303092A (https=)
CA (1) CA2422303A1 (https=)
DE (1) DE60317606T2 (https=)
MX (1) MXPA03002864A (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012093821A3 (ko) * 2011-01-04 2013-01-24 주식회사 바이오트라이온 초기유방암의 예후 예측용 유전자 및 이를 이용한 초기유방암의 예후예측 방법

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1361433A3 (en) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
US20050003422A1 (en) * 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
CA2556890C (en) * 2004-02-20 2017-04-25 Veridex, Llc Breast cancer prognostics
US20050244872A1 (en) * 2004-04-23 2005-11-03 Exagen Diagnostics, Inc. Breast cancer gene expression biomarkers
US20070130694A1 (en) * 2005-12-12 2007-06-14 Michaels Emily W Textile surface modification composition
WO2007088971A1 (ja) * 2006-02-03 2007-08-09 Messengerscape Co., Ltd. がん予後判定に利用できる遺伝子群
CN101631454A (zh) 2006-12-08 2010-01-20 衣阿华州立大学研究基金公司 参与硝酸盐吸收和代谢的植物基因
CN105224827B (zh) * 2008-07-01 2019-12-24 小利兰·斯坦福大学托管委员会 用于发展ivf治疗协议的分析数据的计算机系统和存储介质
ES2338843B1 (es) * 2008-07-02 2011-01-24 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas Huella genomica de cancer de mama.
GB0821787D0 (en) * 2008-12-01 2009-01-07 Univ Ulster A genomic-based method of stratifying breast cancer patients
US8790916B2 (en) 2009-05-14 2014-07-29 Genestream, Inc. Microfluidic method and system for isolating particles from biological fluid
CA2818890C (en) 2010-11-23 2022-07-12 Krisani Biosciences (P) Ltd Method and system for prognosis and treatment of diseases using portfolio of genes

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US635152A (en) * 1899-06-05 1899-10-17 Melancthon S Shotwell Car-body bolster.
US6350576B1 (en) * 1994-12-20 2002-02-26 Cold Spring Harbor Laboratory Cancer detection probes
EP1505159B1 (en) 1995-03-17 2008-05-28 John Wayne Cancer Institute Detection of breast metastases with a multiple marker assay
US6275814B1 (en) * 1996-11-27 2001-08-14 Investment Strategies Network Investment portfolio selection system and method
US6003018A (en) * 1998-03-27 1999-12-14 Michaud Partners Llp Portfolio optimization by means of resampled efficient frontiers
US6037129A (en) * 1998-05-28 2000-03-14 Medical University Of South Carolina Multi-marker RT-PCR panel for detecting metastatic breast cancer
US6175624B1 (en) * 1999-03-05 2001-01-16 Centurion International, Inc. Method for connecting a battery circuit in a cellular telephone
MXPA01009369A (es) 1999-03-15 2003-06-06 Eos Biotechnology Inc Nuevos metodos para el diagnostico del cancer colorectal, composiciones, y metodos para seleccionar moduladores del cancer colorectal.
CA2383592A1 (en) * 1999-03-31 2000-10-05 Curagen Corporation 2384891 acids including open reading frames encoding polypeptides; orfx
US6175824B1 (en) * 1999-07-14 2001-01-16 Chi Research, Inc. Method and apparatus for choosing a stock portfolio, based on patent indicators
US6353152B1 (en) * 1999-07-15 2002-03-05 Research Development Foundation Corticotropin releasing factor receptor 2 deficient mice and uses thereof
WO2003070889A2 (en) * 2002-02-19 2003-08-28 Idec Pharmaceuticals Corporation Prostate specific genes and the use thereof in design or therapeutics
US20050054826A1 (en) * 2003-05-19 2005-03-10 Rosetta Inpharmatics Llc Human diaphanous-3 gene and methods of use therefor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012093821A3 (ko) * 2011-01-04 2013-01-24 주식회사 바이오트라이온 초기유방암의 예후 예측용 유전자 및 이를 이용한 초기유방암의 예후예측 방법

Also Published As

Publication number Publication date
DE60317606T2 (de) 2008-10-23
JP2003325192A (ja) 2003-11-18
EP1367138B1 (en) 2007-11-21
CN1495274A (zh) 2004-05-12
US20030190656A1 (en) 2003-10-09
CA2422303A1 (en) 2003-09-29
AU2003203557B2 (en) 2007-05-24
EP1367138A3 (en) 2004-03-10
AR039213A1 (es) 2005-02-09
DE60317606D1 (de) 2008-01-03
US7473526B2 (en) 2009-01-06
MXPA03002864A (es) 2004-08-11
EP1367138A2 (en) 2003-12-03
BR0303092A (pt) 2004-09-08
AU2003203557A1 (en) 2003-10-23

Similar Documents

Publication Publication Date Title
KR20030078799A (ko) 암 진단 패널
KR20030078803A (ko) 마커의 선택
US12595516B2 (en) Neuroendocrine tumors
Bie et al. The accuracy of survival time prediction for patients with glioma is improved by measuring mitotic spindle checkpoint gene expression
JP5237076B2 (ja) 乳癌患者の診断および予後
JP5405110B2 (ja) 原発不明がんの原発巣を同定するための方法および材料
US10266902B2 (en) Methods for prognosis prediction for melanoma cancer
JP4913331B2 (ja) 結腸直腸癌の予後
JP5089993B2 (ja) 乳癌の予後診断
JP2007049991A (ja) 乳癌の骨への再発の予測
JP2008521412A (ja) 肺癌予後判定手段
JP2009528825A (ja) デュークスｂ大腸がんの再発を予測するための分子的解析
JP2011509689A (ja) Ｉｉ及びｉｉｉ期結腸癌の分子病期分類並びに予後診断
EP2419540B1 (en) Methods and gene expression signature for assessing ras pathway activity
KR20030078805A (ko) 유방암 예후 포트폴리오
US20050186577A1 (en) Breast cancer prognostics
JP2004344171A (ja) 乳癌予後予測法
JP2007508008A (ja) 乳癌診断に関する物質および方法
EP1679382A2 (en) Panel of nucleic acid sequences for cancer diagnosis
CN113278705A (zh) 检测口腔鳞癌的基于生物标志物的诊断产品及其应用
Mansmann et al. Classification and prediction in pharmacogenetics–context, construction and validation
Bie et al. The Accuracy of Survival Time Prediction for Patients with Glioma Is Improved by Measuring

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203

WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid
R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000